Amgen will pay an initial $55m and up to $666m in cash subject to milestones.

US-listed drugs group Amgen has agreed to acquire Rodeo Therapeutics, a US-based small-molecule therapy developer for tissue, for up to $721m. Amgen will pay an initial $55m and up to $666m in cash subject to milestones. In July 2017, Rodeo raised $5.9m in series A financing from investors including pharmaceutical firms AbbVie, Eli Lilly, Johnson & Johnson…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.